Transcription of Title: A Phase 1, Randomized, Double-Blind, Placebo ...
{{id}} {{{paragraph}}}
Example: bankruptcy
Title: A Phase 1, Randomized, Double-Blind, Placebo ...
This may include, but is not limited to, redaction of the following: Title: A Phase 1, randomized , double - blind , Placebo - controlled , Safety, Tolerability andPharmacokinetic Study of Escalating Single and Multiple Doses of TAK-653 in HealthySubjectsNCT Number: NCT02561156 Protocol Approve Date: 24 March 2017 Certain information within this protocol has been redacted (ie, specific content is masked irreversibly from view with a black/blue bar) to protect either personally identifiable information or company confidential information. Named persons or organizations associated with the information, such as scales or coding systems, which are considered confidential information under prior agreements with license information as needed to protect confidentiality of Takeda or partners, personalinformation, or to otherwise protect the integrity of the clinical PAGECONFIDENTIALPROTOCOL AMENDMENTA Phase 1, randomized , double - blind , Placebo - controlled , Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of TAK-653 in Healthy SubjectsPhase 1 TAK-653 Escalating Single
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of TAK-653 in Healthy Subjects Phase 1 TAK-653 Escalating Single and Multiple Dose Study in Healthy Subjects Sponsor: Takeda Development Centre Europe Ltd. 61 Aldwych London, WC2B 4AE United Kingdom
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: